First Author Publications

Waddell T, Moorcraft SY, Cunningham D  ‘Drug Evaluation: Potential role of rilotumumab in the treatment of gastric cancer’  Immunotherapy 2014; 6 (12): 1243-1253

Waddell T  ‘Targeting EGFR in colorectal cancer: beyond KRAS exon 2’  Lancet Oncol 2014; 15 (6): 540-541

Waddell T, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D  ‘Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up’  Ann Oncol 2013; 24 (Suppl 6): vi57-63 (simultaneously published in Eur J Surg Oncol and Radiother Oncol)

Waddell T, Chau I, Cunningham D et al  ‘Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial’  Lancet Oncol 2013; 14 (6): 481-489

Waddell T, Cunningham D  ‘Evaluation of regorafenib in colorectal cancer and GIST’  Lancet 2013; 381 (9863): 273-275

Waddell T, Cunningham D  ‘Impact of targeted neoadjuvant therapies in the treatment of solid organ tumours’  Br J Surg 2013; 100 (1): 5-14

Waddell TS, Cunningham D  Chemotherapy: perioperative therapy improves gastroesophageal cancer survival’  Nat Rev Clin Oncol 2011; 7; 8(8): 450-452

Waddell T, Kotsori A, Constantinidou A et al  Trastuzumab beyond progression in HER2-positive advanced breast cancer: the Royal Marsden experience’  Br J Cancer 2011; 104(11): 1675-1679

Waddell T, Gollins S, Soe W et al  Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study’  Canc Chemother and Pharmacol 2011; 67 (5): 1111-1117

Waddell T, Saunders M  Conference report: world congress on gastrointestinal cancer (WCGIC) 2008’  GI Canc Abstr 2008; 23: 2-4

Waddell TS, Hislop WS  Analysis of alcohol-related admissions in gastroenterology, cardiology and respiratory medicine’  Scot Med J  2003; 48: 114-116

Other Publications

Grenader T, Waddell T, Peckitt C et al  ‘Prognostic value of neutrophil to lymphocyte ratio in advanced oesophago-gastric cancer: exploratory analysis of the REAL-2 trial’  Ann Oncol 2016; epub ahead of print

Moorcraft SY, Fontana E, Cunningham D et al  ‘Characterising timing and pattern of relapse following surgery for localised oesophagogastric adenocarcinoma: a retrospective study’  BMC Cancer 2016; 16: 112

Fontana E, Smyth EC, Cunningham D et al  ‘Improved survival in resected oesophageal and gastric adenocarcinomas over a decade: the Royal Marsden experience 2001-2010’  Gastric Cancer 2015; epub ahead of print

Smyth EC, Waddell TS, Cunningham D  ‘Optimal management of oesophageal adenocarcinoma: should we be CROSS?’ J Clin Oncol 2014; 32 (27): 3080-1

Okines A, Gonzalez-de-Castro D, Cunningham D et al  ‘Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials’  Eur J Canc 2013; 49 (9): 2116-2125

Okines A, Thompson L, Cunningham D et al  ‘Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial’  Ann Oncol 2013; 24 (5): 1253-1261

Sheikh H, Valle J, Waddell T et al  Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer’  Br J Cancer 2008; 99: 577-583

Clarke R, Waddell T et al  A postcode lottery still exists for cancer patients with ‘exceptional circumstances’  Clin Onc 2008; 20 (10): 771-772